Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials

The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton’s tyrosine kinase inhibitors, or BCL2 inhibitors alone or combined with an anti-CD20 monoclonal antibody. However, the availability of multiple choices for the first-line setting and a lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzuto, Andrea, Pirrera, Angelo, Gigliotta, Emilia, Mancuso, Salvatrice, Vullo, Candida, Camarda, Giulia Maria, Rotolo, Cristina, Roppolo, Arianna, Spoto, Corinne, Gentile, Massimo, Botta, Cirino, Siragusa, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298034/
https://www.ncbi.nlm.nih.gov/pubmed/37373078
http://dx.doi.org/10.3390/ijms24129930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298034/
https://www.ncbi.nlm.nih.gov/pubmed/37373078
http://dx.doi.org/10.3390/ijms24129930

Ejemplares similares